NeuroDerm Priced, Nasdaq: NDRM
Developing a liquid formulation of levodopa for Parkinson's disease.
Industry: Health Care
First Day Return: -8.5%
NDRM
Developing a liquid formulation of levodopa for Parkinson's disease.
| IPO Data | |
|---|---|
| IPO Date | 11/13/2014 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $45 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | Rehovot, Israel |
| Founded | 2003 |
| Employees at IPO | 21 |
| Website www.neuroderm.com | |
IPO News for NeuroDerm
- Race to the Finnish line: Parkinson's biotech Biotie Therapies files for a $60 million US IPO 05/14/15
- Parkinson's biotech Civitas Therapeutics officially withdraws IPO; acquired by Acorda for $525 million 12/11/14
- US IPO Weekly Recap: Virgin America flies high as IPO market reaches 250 with 9 new offerings 11/14/14
NeuroDerm (NDRM) Performance
